FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
Summary by Hastings Tribune
2 Articles
2 Articles
FDA Grants Breakthrough Device Designation to Castle Biosciences’ DecisionDx®-Melanoma Test
FRIENDSWOOD, Texas, July 23, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its DecisionDx-Melanoma test has been granted Breakthrough Device designation from the U.S. Food…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center1Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium